The International AIDS Vaccine Initiative (IAVI) announced the start of a Phase I clinical trial to test a novel HIV vaccine candidate, an advance in vaccine design enabled by Scripps Research discoveries.

In a breakthrough with applicability across many flu strains, researchers find a potential small molecule that mimics antibodies to treat disease.